Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Report and Forecast 2024-2032

Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Size

The attention deficit hyperactivity disorder (ADHD) treatment market was valued at USD 14.64 billion in 2023, driven by heightened awareness of ADHD among people across the 8 major markets. The market is expected to grow at a CAGR of 5.1% during the forecast period of 2024-2032, with values likely to reach USD 22.91 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook

• The market demand for ADHD treatment is increasing as the number of diagnosed ADHD cases has collectively risen across the major markets.

• Rising awareness among parents about the brain disorder is significantly contributing to the market growth of the treatment.

• The market value is influenced by the escalating number of FDA approvals for the management of the condition.

Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Overview

Attention deficit hyperactivity disorder (ADHD) is a brain disorder which hampers the ability of a person to pay attention to things, along with behaviour control. It is among the most common brain disorders diagnosed in children. Both children and adults are affected by the condition, however, it is commonly diagnosed in children which further continues to adulthood.

Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Growth Drivers

Rising Incidence of the Disease

The increasing rates of ADHD diagnoses are highly contributing to the increased demand for ADHD treatment. However, the reason behind the heightening number of ADHD diagnoses is the increasing recognition of the condition. Parents are paying more attention to their children, therefore, the diagnosis rate of the condition is rising. As per the report published by the Centers for Disease Control and Prevention in May 2024, 1 in every 9 children in the United States between the age of 3-17 have been diagnosed with attention deficit hyperactivity disorder (ADHD).

Additionally, in 2022, a report by the American public broadcasting organization revealed that nearly 7.1 million people (including kids) were diagnosed with ADHD.

Additionally, the window of treatment for children suffering from ADHD is also wide open, as it was also found by the study that the total number of children taking medications was only half the number of children diagnosed with ADHD. This highlights a wide gap of unmet actions and initiatives to spread the awareness about the condition, propelling the possibilities of market expansion.

Adoption of Novel Therapeutics

As the healthcare domain is witnessing instrumental strides towards technological advancements, the ADHD treatment market is also influenced. The market players like Akili are coming to the forefront and establishing a new benchmark in the ADHD treatment market. Akili Interactive, a prescription-based digital medicine company announced the 510k clearance of its phone-based video game in June 2024. The game is curated and designed to manage attention-deficit hyperactivity disorder (ADHD). As the first-ever video game for ADHD management, it showcased notable efficacy of 83% clinical response in clinical trials.  Such innovations have great potential in improving patient health as well as create huge market demand and support the upward trajectory of the market in the forecast period.

Surge in Drug Approvals to Meet Rising Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Demand

With increasing awareness, the diagnoses incidence is collectively booming. The market value is further fuelled by the escalating number of drug approvals for effective management of the disease. In May 2024, the US Food and Drug Administration (FDA) gave a nod to Tris Pharma’s Onyda XR (clonidine hydrochloride) indicated for the treatment of attention deficit hyperactivity disorder (ADHD). The drug is the first ever and only liquid stimulant ADHD medication receiving FDA approval in the United States. It is a once-a-day extended-release oral suspension with nighttime dosing indicated as a monotherapy for pediatric patients 6 years and older. Such drug approvals by the regulatory authorities are anticipated to propel market growth in the forecast period.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Segmentation

Market Breakup by Treatment Type

• Stimulants
  • Amphetamine
  • Methylphenidate
  • Dextroamphetamine
  • Dexmethylphenidate
  • Lisdexamfetamine Dimesylate

• Non-Stimulants
  • Atomoxetine
  • Bupropion
  • Guanfacine
  • Clonidine

Market Breakup by Age Group

• Adult

• Children

Market Breakup by Gender

• Male

• Female

Market Breakup by Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Others

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

• India

Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Share

Market Share by Treatment Type to Witness Substantial Growth

The market segmentation based on treatment type is broadly segmented into stimulants and non-stimulants. Stimulants are further divided into Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate and Lisdexamfetamine Dimesylate, whereas, non-stimulants include Atomoxetine, Bupropion, Guanfacine and Clonidine. The stimulants are expected to dominate the market segment as they are highly effective in managing ADHD among both children and adults. Stimulants are commonly preferred by medical professionals due to their proven efficacy in treating the condition and improving patient outcomes.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Analysis by Region

Based on region, the market report offers insights for the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan and India.

In the market segmentation based on region, the United States has the largest market share due to the rising incidence of the condition. The market share is also influenced by the heightened level of awareness among people about the ADHD condition. According to the data released by the U.S Centers for Disease Control and Prevention, 56.9% of children aged between 6-11 years, are currently receiving ADHD treatments.

Leading Players in the Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market

The key features of the market report comprise clinical trial analysis, grants analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:

Takeda Pharmaceutical Company Limited

Headquartered in Tokyo, Japan, Takeda is a multinational pharmaceutical company. It is the third-largest pharmaceutical company in Asia. The company offers plasma-derived treatment therapies and vaccines focused on medical conditions such as oncology, rare diseases, neuroscience, and gastroenterology.

Aytu BioPharma, Inc.

Aytu BioPharma, Inc. headquartered in Denver, Colorado, is a dynamic speciality pharmaceutical company with an expanding portfolio of prescriptions primarily focused on complex conditions such as ADHD and other common conditions.

Eli Lilly and Company

Headquartered in Indiana, United States, Eli Lily and Company is a pharmaceutical company with an expanding foot reach in more than 125 countries. With primary drug offerings for conditions like diabetes, the company is also known for its clinical depression drugs like Prozac.

Pfizer Inc.

Headquartered in Manhattan, New York, Pfizer is a multinational pharmaceutical and biotechnology corporation. The company offers drugs and vaccines for the treatment of conditions such as immunology, oncology, cardiology, endocrinology, and neurology.

Other key players in the market include Noven Pharmaceuticals Inc. Supernus Pharmaceuticals, Inc., Johnson & Johnson Services Inc., Novartis AG, Curemark, LLC, Highland Therapeutics Inc., and GlaxoSmithKline Plc.

Key Highlights of the Report

Key Questions Answered in the Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market

• What was the attention deficit hyperactivity disorder (ADHD) treatment market value in 2023? 
• What is the attention deficit hyperactivity disorder (ADHD) treatment market forecast outlook for 2024-2032? 
• What are the regional markets covered in the EMR report? 
• What is market segmentation based on treatment type? 
• What is the market breakup based on gender?
• What is the market breakup based on age group? 
• Who are the major distribution channels in the market? 
• What are the major factors aiding the attention deficit hyperactivity disorder (ADHD) treatment market demand?  
• How has the market performed so far and how is it anticipated to perform in the coming years? 
• What are the market's major drivers, opportunities, and restraints?  
• Which regional market is expected to lead the market share in the forecast period?  
• Which country is expected to experience expedited growth during the forecast period?  
• What are the major attention deficit hyperactivity disorder (ADHD) treatment market trends? 
• Which treatment type will dominate the market share?  
• Which distribution channel is expected to have a high market value in the coming years? 
• Which end-user is projected to contribute to the highest market growth? 
• Who are the key players involved in the attention deficit hyperactivity disorder (ADHD) treatment market? 
• What is the patent landscape of the market? 
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?